Medication info
Telostop Plus Tablet 80/5/10 Milligrams

Telostop Plus Tablet 80/5/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Active

MFDS item code 201801978 · Approved 2018.05.10 · Insurance code 642905980

Summary

Main use
Treatment of hypertension and dyslipidemia, and inhibition of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience. ○ Telmisartan/Amlodipine Combination Before treatment with the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of the day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and inhibition of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy using Telmisartan and Amlodipine and patients who require concomitant treatment with Rosuvastatin. The Telmisartan/Amlodipine combination effectively lowers blood pressure to treat hypertension, while Rosuvastatin helps manage hypercholesterolemia and dyslipidemia. Additionally, Rosuvastatin contributes to delaying the progression of atherosclerosis and reducing the risk of stroke, myocardial infarction, and arterial revascularization in high-risk patients. As a result, this medication is effective in maintaining cardiovascular health and preventing complications. Therefore, it is used to treat patients with both hypertension and dyslipidemia.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience. ○ Telmisartan/Amlodipine Combination Before treatment with the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of the day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients.

Precautions

This medication can cause severe harm to the fetus during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this medication or similar drugs, or a history of angioedema, should not take this medication. Patients with severe impairment of liver or kidney function, severe heart disease, and certain muscle diseases should also avoid this medication. Elderly patients or patients with hyperkalemia, as well as those with mild liver dysfunction, need to use this medication with special precautions. If symptoms like muscle pain, weakness, or cramps occur while taking this medication, consult a doctor immediately, and if necessary, confirm muscle damage through blood tests. Regular liver function tests are needed since this medication could be discontinued if liver dysfunction is suspected or if liver enzyme levels are elevated. This medication may interact with other drugs, so it is essential to inform the doctor if you are taking blood pressure medications, diuretics, lithium, warfarin, certain antibiotics, immunosuppressants, etc. Women of childbearing age should use appropriate contraception while taking this medication and should ideally avoid it during breastfeeding. The safety and efficacy in children and adolescents under 18 years of age have not been sufficiently established, so it is not recommended for them. Overdose of this medication may cause hypotension, dizziness, and renal impairment. Therefore, care should be taken to not exceed the recommended dosage, and in case of doubt, visit a medical institution immediately. This medication should be kept out of reach of children and should not be transferred to other containers for safety.

Side effects

Viral upper respiratory infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, paresthesia, involuntary muscle contraction, erectile dysfunction, increased sweating, flushing, allergy, fever, leg pain, malaise, palpitations, angioedema, asthma, bronchitis, epistaxis, dermatitis, rash, eczema, pruritus, frequent urination, cystitis, cerebrovascular disease, visual disturbance, conjunctivitis, ear pain, angioedema, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, myasthenia, burning sensation, malaise, rigidity, weight gain, weight loss, arthralgia, osteoarthritis, muscle cramps, sexual dysfunction, insomnia, neuralgia, depression, abnormal dreams, anxiety, depersonalization, angioedema, polymorphic erythema, erythematous rash, papular rash, diplopia, ocular pain, urinary incontinence, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, headache, dizziness, constipation, nausea, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, myasthenia, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, memory loss, peripheral neuropathy, cough, diarrhea, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that prevents light exposure. It is also important to maintain room temperature, between 1 and 30 degrees Celsius, while storing the medication to preserve its efficacy.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.